Literature DB >> 17301614

Drug-induced acute angle closure glaucoma.

Yves Lachkar1, Walid Bouassida.   

Abstract

PURPOSE OF REVIEW: Acute angle closure glaucoma is a potentially blinding side effect of a number of local and systemic drugs, including adrenergic, both anticholinergic and cholinergic, antidepressant and antianxiety, sulfa-based, and anticoagulant agents. The purpose of this article is to bring this condition to the attention of clinicians using these compounds as well as ophthalmologists called to see the patient. RECENT
FINDINGS: Acute angle closure glaucoma due to pupillary block, treatable by peripheral iridotomy, can be caused by adrenergic agents, either locally (phenylephrine drops, nasal ephedrine, or nebulized salbutamol) or systemically (epinephrine for anaphylactic shock), drugs with anticholinergic effects including tropicamide and atropine drops, tri and tetracyclic antidepressants, and cholinergic agents like pilocarpine. A novel anticholinergic form is the use of periocular botulinum toxin diffusing back to the ciliary ganglion inhibiting the pupillary sphincter. Sulfa-based drugs (acetazolamide, hydrochlorothiazide, cotrimoxazole, and topiramate) can cause acute angle closure glaucoma by ciliary body edema with anterior rotation of the iris-lens diaphragm. Iridotomy is not effective.
SUMMARY: Most attacks of acute angle closure glaucoma involving pupillary block occur in individuals that are unaware that they have narrow iridocorneal angles. Practitioners using any of the above drugs should be aware of their potential to cause acute angle closure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301614     DOI: 10.1097/ICU.0b013e32808738d5

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  53 in total

1.  Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation.

Authors:  James C Liu; Wesley Green; Gregory P Van Stavern; Susan M Culican
Journal:  Can J Ophthalmol       Date:  2017-08       Impact factor: 1.882

Review 2.  Non-steroidal drug-induced glaucoma.

Authors:  M R Razeghinejad; M J Pro; L J Katz
Journal:  Eye (Lond)       Date:  2011-06-03       Impact factor: 3.775

3.  Acute angle closure glaucoma presented with nausea and epigastric pain.

Authors:  Evangelos Cholongitas; Chrysoula Pipili; Maria Dasenaki
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

4.  Bilateral acute angle closure glaucoma associated with hydrochlorothiazide-induced hyponatraemia.

Authors:  Sylvia H Chen; Rustum Karanjia; Robert L Chevrier; David H Marshall
Journal:  BMJ Case Rep       Date:  2014-12-04

5.  Evidence for Clinicians: Nebulized epinephrine for croup in children.

Authors:  Atsushi Kawaguchi; Ari Joffe
Journal:  Paediatr Child Health       Date:  2015 Jan-Feb       Impact factor: 2.253

6.  Bilateral simultaneous acute angle closure attack triggered by an over-the-counter flu medication.

Authors:  Simona Delia Nicoară; Ioana Damian
Journal:  Int Ophthalmol       Date:  2017-07-01       Impact factor: 2.031

7.  Bilateral acute angle closure glaucoma precipitated by over the counter oral decongestant.

Authors:  Elliott Y Ah-Kee; James F Li Yim
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

8.  Characterizing Current Attitudes and Practices for Human Subject Safety in Studies Involving Pupil Dilation.

Authors:  Jacob Szpernal; Joseph Carroll; Ryan Spellecy; Jane A Bachman Groth
Journal:  J Empir Res Hum Res Ethics       Date:  2020-11-02       Impact factor: 1.742

9.  Efficacy and tolerability of nortriptyline in the management of neuropathic corneal pain.

Authors:  M Cuneyt Ozmen; Gabriela Dieckmann; Stephanie M Cox; Ramy Rashad; Rumzah Paracha; Nedda Sanayei; Melina I Morkin; Pedram Hamrah
Journal:  Ocul Surf       Date:  2020-08-27       Impact factor: 5.033

10.  Noncosmetic periocular therapeutic applications of botulinum toxin.

Authors:  Pelin Kaynak-Hekimhan
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.